Hypericin-mediated photodynamic therapy of pituitary tumors

preclinical study in a GH4C1 rat tumor model.

Chad D. Cole, James Liu, Xiaoming Sheng, Steven S. Chin, Meic H. Schmidt, Martin H. Weiss, William T. Couldwell

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE: Hypericin-mediated photodynamic therapy (PDT) is receiving greater interest as a potential treatment for a variety of tumors and nonmalignant disorders. PDT involves systemic administration of a photosensitizer that selectively accumulates within tumor tissue followed by focal light activation. In the presence of molecular oxygen, a photochemical reaction generates a reactive oxygen species that induces apoptosis in target cells. The purpose of this preclinical study was to evaluate the efficacy of hypericin-mediated PDT for treatment of pituitary adenoma in a rodent model. METHODS: Wistar-Furth rats were implanted with a pituitary adenoma rat cell line, GH4C1. Tumor masses were allowed to develop over 28 days; rats with tumors of comparable sizes were then assigned to three treatment groups: control (neither hypericin nor light); light only; and hypericin and light. Hypericin was administered in four doses (1 mg/kg) at 28-h intervals prior to light exposure, wherein those rats treated with light were exposed to a light source four hours after the last hypericin dose. Tumor size was measured up to 12 days after treatment. RESULTS: Over the short interval examined, hypericin-mediated PDT was not effective against large tumors greater than 1 cm(3), but this treatment significantly slowed tumor growth for tumors less than 1 cm(3). Histological evaluation and TUNEL assay of the treated tumor identified apoptotic clusters on the periphery of the PDT-treated specimens. CONCLUSIONS: Hypericin-mediated PDT shows promise in its effectiveness in the treatment of residual small tumor rests.

Original languageEnglish (US)
Pages (from-to)255-261
Number of pages7
JournalJournal of neuro-oncology
Volume87
Issue number3
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Photochemotherapy
Pituitary Neoplasms
Light
Neoplasms
Inbred WF Rats
Therapeutics
hypericin
Photosensitizing Agents
In Situ Nick-End Labeling
Residual Neoplasm
Rodentia
Reactive Oxygen Species
Apoptosis
Oxygen
Cell Line
Control Groups
Growth

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology
  • Oncology
  • Cancer Research

Cite this

Cole, Chad D. ; Liu, James ; Sheng, Xiaoming ; Chin, Steven S. ; Schmidt, Meic H. ; Weiss, Martin H. ; Couldwell, William T. / Hypericin-mediated photodynamic therapy of pituitary tumors : preclinical study in a GH4C1 rat tumor model. In: Journal of neuro-oncology. 2008 ; Vol. 87, No. 3. pp. 255-261.
@article{62793dfb8f0b434f92ad5ec392aa88b5,
title = "Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.",
abstract = "OBJECTIVE: Hypericin-mediated photodynamic therapy (PDT) is receiving greater interest as a potential treatment for a variety of tumors and nonmalignant disorders. PDT involves systemic administration of a photosensitizer that selectively accumulates within tumor tissue followed by focal light activation. In the presence of molecular oxygen, a photochemical reaction generates a reactive oxygen species that induces apoptosis in target cells. The purpose of this preclinical study was to evaluate the efficacy of hypericin-mediated PDT for treatment of pituitary adenoma in a rodent model. METHODS: Wistar-Furth rats were implanted with a pituitary adenoma rat cell line, GH4C1. Tumor masses were allowed to develop over 28 days; rats with tumors of comparable sizes were then assigned to three treatment groups: control (neither hypericin nor light); light only; and hypericin and light. Hypericin was administered in four doses (1 mg/kg) at 28-h intervals prior to light exposure, wherein those rats treated with light were exposed to a light source four hours after the last hypericin dose. Tumor size was measured up to 12 days after treatment. RESULTS: Over the short interval examined, hypericin-mediated PDT was not effective against large tumors greater than 1 cm(3), but this treatment significantly slowed tumor growth for tumors less than 1 cm(3). Histological evaluation and TUNEL assay of the treated tumor identified apoptotic clusters on the periphery of the PDT-treated specimens. CONCLUSIONS: Hypericin-mediated PDT shows promise in its effectiveness in the treatment of residual small tumor rests.",
author = "Cole, {Chad D.} and James Liu and Xiaoming Sheng and Chin, {Steven S.} and Schmidt, {Meic H.} and Weiss, {Martin H.} and Couldwell, {William T.}",
year = "2008",
month = "1",
day = "1",
doi = "https://doi.org/10.1007/s11060-007-9514-0",
language = "English (US)",
volume = "87",
pages = "255--261",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Hypericin-mediated photodynamic therapy of pituitary tumors : preclinical study in a GH4C1 rat tumor model. / Cole, Chad D.; Liu, James; Sheng, Xiaoming; Chin, Steven S.; Schmidt, Meic H.; Weiss, Martin H.; Couldwell, William T.

In: Journal of neuro-oncology, Vol. 87, No. 3, 01.01.2008, p. 255-261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hypericin-mediated photodynamic therapy of pituitary tumors

T2 - preclinical study in a GH4C1 rat tumor model.

AU - Cole, Chad D.

AU - Liu, James

AU - Sheng, Xiaoming

AU - Chin, Steven S.

AU - Schmidt, Meic H.

AU - Weiss, Martin H.

AU - Couldwell, William T.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - OBJECTIVE: Hypericin-mediated photodynamic therapy (PDT) is receiving greater interest as a potential treatment for a variety of tumors and nonmalignant disorders. PDT involves systemic administration of a photosensitizer that selectively accumulates within tumor tissue followed by focal light activation. In the presence of molecular oxygen, a photochemical reaction generates a reactive oxygen species that induces apoptosis in target cells. The purpose of this preclinical study was to evaluate the efficacy of hypericin-mediated PDT for treatment of pituitary adenoma in a rodent model. METHODS: Wistar-Furth rats were implanted with a pituitary adenoma rat cell line, GH4C1. Tumor masses were allowed to develop over 28 days; rats with tumors of comparable sizes were then assigned to three treatment groups: control (neither hypericin nor light); light only; and hypericin and light. Hypericin was administered in four doses (1 mg/kg) at 28-h intervals prior to light exposure, wherein those rats treated with light were exposed to a light source four hours after the last hypericin dose. Tumor size was measured up to 12 days after treatment. RESULTS: Over the short interval examined, hypericin-mediated PDT was not effective against large tumors greater than 1 cm(3), but this treatment significantly slowed tumor growth for tumors less than 1 cm(3). Histological evaluation and TUNEL assay of the treated tumor identified apoptotic clusters on the periphery of the PDT-treated specimens. CONCLUSIONS: Hypericin-mediated PDT shows promise in its effectiveness in the treatment of residual small tumor rests.

AB - OBJECTIVE: Hypericin-mediated photodynamic therapy (PDT) is receiving greater interest as a potential treatment for a variety of tumors and nonmalignant disorders. PDT involves systemic administration of a photosensitizer that selectively accumulates within tumor tissue followed by focal light activation. In the presence of molecular oxygen, a photochemical reaction generates a reactive oxygen species that induces apoptosis in target cells. The purpose of this preclinical study was to evaluate the efficacy of hypericin-mediated PDT for treatment of pituitary adenoma in a rodent model. METHODS: Wistar-Furth rats were implanted with a pituitary adenoma rat cell line, GH4C1. Tumor masses were allowed to develop over 28 days; rats with tumors of comparable sizes were then assigned to three treatment groups: control (neither hypericin nor light); light only; and hypericin and light. Hypericin was administered in four doses (1 mg/kg) at 28-h intervals prior to light exposure, wherein those rats treated with light were exposed to a light source four hours after the last hypericin dose. Tumor size was measured up to 12 days after treatment. RESULTS: Over the short interval examined, hypericin-mediated PDT was not effective against large tumors greater than 1 cm(3), but this treatment significantly slowed tumor growth for tumors less than 1 cm(3). Histological evaluation and TUNEL assay of the treated tumor identified apoptotic clusters on the periphery of the PDT-treated specimens. CONCLUSIONS: Hypericin-mediated PDT shows promise in its effectiveness in the treatment of residual small tumor rests.

UR - http://www.scopus.com/inward/record.url?scp=48049122702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049122702&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s11060-007-9514-0

DO - https://doi.org/10.1007/s11060-007-9514-0

M3 - Article

VL - 87

SP - 255

EP - 261

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -